B
Barry D. Lebowitz
Researcher at University of California, San Diego
Publications - 121
Citations - 26749
Barry D. Lebowitz is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Mental health & Complicated grief. The author has an hindex of 47, co-authored 121 publications receiving 24635 citations. Previous affiliations of Barry D. Lebowitz include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider,Pierre N. Tariot,Karen S. Dagerman,Sonia M. Davis,John K. Hsiao,M. Saleem Ismail,Barry D. Lebowitz,Constantine G. Lyketsos,J. Michael Ryan,T. Scott Stroup,David L. Sultzer,Daniel Weintraub,Jeffrey A. Lieberman +12 more
TL;DR: Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
Journal ArticleDOI
Sequenced treatment alternatives to relieve depression (STAR * D): rationale and design
A. John Rush,Maurizio Fava,Stephen R. Wisniewski,Philip W. Lavori,Madhukar H. Trivedi,Harold A. Sackeim,Michael E. Thase,Andrew A. Nierenberg,Frederic M. Quitkin,T. Michael Kashner,David J. Kupfer,Jerrold F. Rosenbaum,Jonathan E. Alpert,Jonathan W. Stewart,Patrick J. McGrath,Melanie M. Biggs,Kathy Shores-Wilson,Barry D. Lebowitz,Louise Ritz,George Niederehe +19 more
TL;DR: STAR*D as discussed by the authors is a multisite, prospective, randomized, multistep clinical trial of outpatients with nonpsychotic major depressive disorder, which compared various treatment options for those who do not attain a satisfactory response with citalopram, a selective serotonin reuptake inhibitor antidepressant.